The XenX irradiator platform has been designed to allow high throughput targeted irradiation studies on cells and small animals. XenX is equipped with a 225 kVp X-ray tube and a 360 degree rotational gantry to allow beam delivery from any angle. Portal imaging allows for a beams eye view of the specimen, and the ability to perform a double exposure technique enables targeting of orthotopic and ectopic tumors with a collimated beam.
An upgrade from a standard, fixed source, single planar X-ray cabinet irradiator. The XenX allows investigators to deliver beams of radiation in a clinically relevant and translatable way. These techniques result in a more 3D conformal dose to the target area, while drastically minimizing normal tissue and surrounding tissue toxicity. With the ability to deliver a beam or radiation from any angle, XenX allows you to investigate and answer questions that were otherwise unattainable with a fixed beam cabinet irradiator.
Unlike any fixed source cabinet irradiator, XenX pairs X-ray imaging with a 360° degree rotational gantry for accurate targeting of an X-ray beam. XenX utilizes a portal imaging camera and X-ray technology to acquire an image of the specimen resulting in visualization and validation of the target. Prior to the development of cone beam-CT imaging, clinical radiation oncology practice utilized an imaging technique called the “double exposure”. Here an open field X-ray image, and collimated X-ray image are overlaid to verify the treatment area. This technique is easily achieved with XenX and is your first step into image guidance.
A fast simple dose calculator based on depth in tissue is a standard feature on XenX. The depth can be measured on the lateral portal image. The treatment time will be calculated based on the measured depth.
XenX enables investigators from various backgrounds to perform clinically relevant research in a preclinical laboratory setting. The ability to mimic clinical radiation practice in an in vivo model allows for investigation of research end points that have not been attainable up until now. Adopting clinical techniques like imaging, target localization, and avoidance of normal tissue toxicity will only drive the field and understanding of radiation effects to the tumor forward.
XENX will greatly improve the accuracy and reproducibility of in vitro experiments. Most radiation research systems have a fixed X-ray source, which can result in beam attenuation and uneven dose distribution to the cell suspension. The XENX’s 360 degree rotating gantry allows investigators to account for this by giving the option of irradiating from above and underneath the flask. This technique ensures a uniform dose to all suspended and adherent cells.
For those experiments that require stacking plates, the stack can be irradiated from top and bottom, or side to side. In this configuration, the dose uniformity is within 6% across a 6cm stack of plates; which vastly increases throughput while maintaining a constant dose.
XENX enables researchers to image and target both ectopic and orthotopic tumors in small animal models in a way that has previously been unattainable. The ability of the gantry to rotate 360°, and bed movement in the X, Y, Z, and Θ direction allows for non-coplanar beam delivery from any angle. With the ability to image and irradiate up to 3 mice (or 1 rat) simultaneously, XENX allows investigators to perform accurate and reproducible experiments in a high throughput manner. Aside from high resolution cone beam CT imaging. XENX also employs portal imaging which provides fluoroscopic X-ray imaging in a ‘beams eye view’. Technological advancements of the system such as the motorized variable collimator and respiratory gating system allow for a more dynamic and conformal dose to the targeted area.
XenX is available with a range of fixed collimators, or a variable collimator. The variable collimator allows the user to simply adjust the X-ray field to irradiate only the target, and minimize dose to other tissue. With a beam size from 0.0mm to 4 cm x 8cm the system is capable of targeting whole organs xenographs or specific orthotropic tumors.
Throughput is accelerated by using the built in X-ray Field light to align the target. Fixed collimators from 5mm give a quick and efficient beam size, with minimal scatter.
The use of collimators and multiple beam arrangements have led to much higher fractionated doses being delivered. Several groups have proved that clinical dose regimes of up 60Gy can be delivered over a 7 week period compared to conventional lead cut-out based experiments.
There have been over 100 articles published with the help of the SARRP and Xenx. For the full list of articles please click here to be directed to our publication resource page.
External: W-148 cm, D-104 cm, H-205 cm
Total Weight Shielded: Cabinet: 2200 kg
Total Weight Unshielded: Cabinet: 360 kg
Treatment distances: 30-38cm or 80cm FSD
Maximum Field Size: 18 cm circle at 35 cm FSD
Tube Voltage: 20-220 kV
Tube Current: 0-25 mA
Maximum Power Output: 3 kW
Mobile Built on wheels for simple transport
Manual Stage Z direction manual movements
Control Interface Operates X-rays
The XenX irradiator platform has been designed to allow high throughput targeted irradiation studies on cells and small animals. Check out the rest of our Life Sciences range.
We have found SARRP an extremely valuable resource for pre-clinical work in which we aim to mimic clinical treatment regimens as closely as possible. SARRP enables efficient, accurate and reproducible pre-clinical radiotherapy that is especially valuable for assessing drug-radiation combinations in realistic schedules. We have been very impressed by the user-friendly interface in MuriPlan, which is straightforward for users and can be interfaced with imaging modalities such as MRI and bioluminescence for optimised image-guided planning. SARRP has become central to our translational pipeline in radiation biology and comes with extremely good support and maintenance to take the stress out of running large pre-clinical experiments.
SARRP has really made a significant impact in our lab, the ability to accurately target small volumes with image guidance hasn’t been possible before and we are now constantly evolving our approaches to leverage the technology to its maximum potential. Clearly our ability to delivery clinically relevant radiotherapy treatments in preclinical models has taken a major step forward, it up to us as a research community to translate this to the next generation of clinical innovatives
We have been using the CIX2 X-ray cabinet for some years for cell culture experiments, and it is one of the most frequently used machines in our lab. In my opinion, the x-ray irradiator is a great tool for the irradiation of cells in our research lab. The cabinet runs very stable and is easy to operate (even for non-experienced visitors) and offers all options needed for our research making it extremely user-friendly. The possibility to change the filters quickly and to work with different distances away from the x-ray tube markedly enlarges the spectrum of experiments, which can be performed, and the safety aspect is hereby a big advantage. Furthermore, the technical support of X-Strahl is an outstanding example of good customer service.
The irradiation devices developed by Xstrahl for radiobiological research, both in vitro and in vivo, certainly are of outstanding quality in this field of research. We use the Xstrahl SARRP system successfully for our in-vivo-research on orthotopic small animal tumour models. With this system we are able to mimic the clinical situation and especially irradiation in mice much more precisely and easier than in former times. So it helps us to make our research more reliable and more clinically relevant. From my point of view, the customer service provided by Xstrahl is close to perfect. All in all, the possibilities provided by Xstrahl's irradiation equipment, e.g to closely mimic the radiotherapeutic clinical routine in small animal models (CT-based treatment planning with the SARRP system) is absolutely outstanding.
Prior to acquisition of the SARRP we were left with an obvious and significant void in our pre-clinical arsenal to investigate existing and novel cancer therapies. The technological similarity of the SARRP with the medical systems in our clinic and availability of ongoing technical support from Xstrahl were decisive factors. The SARRP forms an integral part of our translational research pipeline and will greatly expand the capacity, potential and quality of our cancer and radiation research.